• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prior SARS-CoV-2 infection balances immune responses triggered by four EMA-approved COVID-19 vaccines: An observational study.

作者信息

Lozano-Rodríguez Roberto, Terrón-Arcos Verónica, Montalbán-Hernández Karla, Casalvilla-Dueñas José Carlos, Bergón-Gutierrez Marta, Pascual-Iglesias Alejandro, Quiroga Jaime Valentín, Aguirre Luis A, Pérez de Diego Rebeca, Vela-Olmo Carmen, López-Morejón Lissette, Martín-Quirós Alejandro, Del Balzo-Castillo Álvaro, Peinado-Quesada María A, García-Garrido Miguel A, Gómez-Lage Laura, Herrero-Benito Carmen, Llorente-Fernández Irene, Martín-Miguel Gema, Torrejón Margarita, Cubillos-Zapata Carolina, Del Fresno Carlos, Avendaño-Ortiz José, López-Collazo Eduardo

机构信息

The Innate Immune Response Group, IdiPAZ, La Paz University Hospital, Madrid, Spain.

Tumour Immunology Lab, IdiPAZ, La Paz University Hospital, Madrid, Spain.

出版信息

Clin Transl Med. 2022 May;12(5):e869. doi: 10.1002/ctm2.869.

DOI:10.1002/ctm2.869
PMID:35538923
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9092002/
Abstract
摘要

相似文献

1
Prior SARS-CoV-2 infection balances immune responses triggered by four EMA-approved COVID-19 vaccines: An observational study.既往感染严重急性呼吸综合征冠状病毒2型可平衡四种欧洲药品管理局批准的新型冠状病毒肺炎疫苗引发的免疫反应：一项观察性研究。
Clin Transl Med. 2022 May;12(5):e869. doi: 10.1002/ctm2.869.
2
Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.基于 SARS-CoV-2 的免疫原性结构蛋白、宿主免疫反应和群体免疫的 COVID-19 疫苗开发的新见解。
Cells. 2021 Oct 29;10(11):2949. doi: 10.3390/cells10112949.
3
Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.接种 COVID-19 mRNA 疫苗后，需要数天才能诱导针对 SARS-CoV-2 的高特异性体液和细胞反应。
Front Immunol. 2021 Oct 4;12:726960. doi: 10.3389/fimmu.2021.726960. eCollection 2021.
4
Postinfectious Immunity After COVID-19 and Vaccination Against SARS-CoV-2.新冠病毒感染后与 SARS-CoV-2 疫苗接种的感染后免疫
Viral Immunol. 2021 Oct;34(8):504-509. doi: 10.1089/vim.2021.0054. Epub 2021 Jul 5.
5
Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.在真实环境中评估灭活 COVID-19 疫苗诱导的 SARS-CoV-2 特异性体液和细胞免疫应答的特征。
Front Immunol. 2021 Dec 22;12:802858. doi: 10.3389/fimmu.2021.802858. eCollection 2021.
6
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.辉瑞-生物科技和 Moderna 疫苗在 SARS-CoV-2 B.1.617.2（Delta）变异株广泛传播之前和期间预防养老院居民感染 SARS-CoV-2 的有效性 - 国家医疗保健安全网络，2021 年 3 月 1 日至 8 月 1 日。
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166. doi: 10.15585/mmwr.mm7034e3.
7
Cross-protective immunity following coronavirus vaccination and coronavirus infection.冠状病毒疫苗接种和感染后的交叉保护免疫。
J Clin Invest. 2021 Dec 15;131(24). doi: 10.1172/JCI151969.
8
Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.慢性透析患者 COVID-19 疫苗接种的免疫原性。
Front Immunol. 2021 Jun 30;12:690698. doi: 10.3389/fimmu.2021.690698. eCollection 2021.
9
SARS-CoV-2-specific immune responses in elderly and immunosuppressed participants and patients with hematologic disease or checkpoint inhibition in solid tumors: study protocol of the prospective, observational CoCo immune study.新型冠状病毒特异性免疫应答在老年和免疫抑制参与者以及血液系统疾病或实体瘤检查点抑制患者中的研究：前瞻性观察性 CoCo 免疫研究的方案。
BMC Infect Dis. 2022 Apr 25;22(1):403. doi: 10.1186/s12879-022-07347-w.
10
Evaluating immunity to SARS-CoV-2 in nursing home residents using saliva IgG.使用唾液 IgG 评估养老院居民对 SARS-CoV-2 的免疫力。
J Am Geriatr Soc. 2022 Mar;70(3):659-668. doi: 10.1111/jgs.17660. Epub 2022 Jan 22.

引用本文的文献

1
Mannan-Decorated Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Antitumor Immune Response by Modulating the Tumor Microenvironment.甘露糖修饰的脂质磷酸钙纳米颗粒疫苗通过调节肿瘤微环境增强抗肿瘤免疫反应。
J Funct Biomater. 2024 Aug 16;15(8):229. doi: 10.3390/jfb15080229.
2
mRNA-1273 boost after BNT162b2 vaccination generates comparable SARS-CoV-2-specific functional responses in naïve and COVID-19-recovered individuals.mRNA-1273 加强针接种后，在未感染过 SARS-CoV-2 的个体和 COVID-19 康复者中产生了可比的 SARS-CoV-2 特异性功能应答。
Front Immunol. 2023 Apr 21;14:1136029. doi: 10.3389/fimmu.2023.1136029. eCollection 2023.
3

本文引用的文献

1
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.Covid-19 疫苗对奥密克戎（B.1.1.529）变异株的有效性。
N Engl J Med. 2022 Apr 21;386(16):1532-1546. doi: 10.1056/NEJMoa2119451. Epub 2022 Mar 2.
2
Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection.新冠病毒疫苗接种和既往感染后对 SARS-CoV-2 的保护作用。
N Engl J Med. 2022 Mar 31;386(13):1207-1220. doi: 10.1056/NEJMoa2118691. Epub 2022 Feb 16.
3
Protection against the Omicron Variant from Previous SARS-CoV-2 Infection.既往感染严重急性呼吸综合征冠状病毒2对奥密克戎变异株的防护作用。
Dynamics of Antibody Responses after Asymptomatic and Mild to Moderate SARS-CoV-2 Infections: Real-World Data in a Resource-Limited Country.
无症状和轻至中度新型冠状病毒感染后的抗体反应动态：资源有限国家的真实世界数据
Trop Med Infect Dis. 2023 Mar 23;8(4):185. doi: 10.3390/tropicalmed8040185.
N Engl J Med. 2022 Mar 31;386(13):1288-1290. doi: 10.1056/NEJMc2200133. Epub 2022 Feb 9.
4
Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant.2019冠状病毒病（COVID-19）疫苗对德尔塔变异株的比较有效性
Clin Infect Dis. 2022 Aug 24;75(1):e623-e629. doi: 10.1093/cid/ciac106.
5
A Cost-Benefit Analysis of COVID-19 Vaccination in Catalonia.加泰罗尼亚地区新冠疫苗接种的成本效益分析
Vaccines (Basel). 2021 Dec 31;10(1):59. doi: 10.3390/vaccines10010059.
6
On the association between COVID-19 vaccination levels and incidence and lethality rates at a regional scale in Spain.西班牙区域层面新冠疫苗接种水平与发病率和致死率之间的关联
Stoch Environ Res Risk Assess. 2022;36(9):2941-2948. doi: 10.1007/s00477-021-02166-y. Epub 2022 Jan 5.
7
Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19.BNT162b2 mRNA 疫苗接种后细胞和体液功能反应在 COVID-19 初治和恢复期患者中具有纵向差异。
Cell Rep. 2022 Jan 11;38(2):110235. doi: 10.1016/j.celrep.2021.110235. Epub 2021 Dec 21.
8
Impact of scaling up SARS-CoV-2 vaccination on COVID-19 hospitalizations in Spain.扩大 SARS-CoV-2 疫苗接种对西班牙 COVID-19 住院人数的影响。
Int J Infect Dis. 2021 Nov;112:81-88. doi: 10.1016/j.ijid.2021.09.022. Epub 2021 Sep 15.
9
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans.人类接种疫苗预防 COVID-19 的免疫机制。
Nat Rev Immunol. 2021 Aug;21(8):475-484. doi: 10.1038/s41577-021-00578-z. Epub 2021 Jul 1.
10
IgA dominates the early neutralizing antibody response to SARS-CoV-2.IgA 在针对 SARS-CoV-2 的早期中和抗体反应中占主导地位。
Sci Transl Med. 2021 Jan 20;13(577). doi: 10.1126/scitranslmed.abd2223. Epub 2020 Dec 7.